Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
China and Cuba strengthen scientific ties (+Photos)
Lazo met with Chinese and Cuban businessmen in Shandong Lukang joint venture, discussing CIGB-814 development and commercial cooperation with BioCubaFarma. The Sino-Cuban International Joint Research Centre for Innovative Medicines was highlighted. Lazo's China visit focuses on parliamentary relations until Nov 12, including high-level meetings. Bilateral biotechnology ties have grown for 20 years, with recent inauguration of BioBridge Medical Technology Co. Ltd in Shijiazhuang.
Award-winning German-Cuban cooperation in cancer therapy
Dr. Gertrudis Rojas Dorantes of the Cuban Centro de Inmunología Molecular visits TU Braunschweig for the sixth time, collaborating with Dr. Maren Schubert to improve cancer treatment using advanced biotechnological methods. Their work has led to five publications and a Research Prize from the Cuban Academy of Sciences, with potential for better cancer therapies within the next decade.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath